Drugs / PPSV23
PPSV23
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 43 trials | ||||||
| Phase 4 | NCT05316831 | Jan 2019 → Jun 2021 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Region Örebro County | Completed | No outcome recorded |
| Phase 4 | NCT03260790 | Oct 2017 → Dec 2020 | asthma | Mayo Clinic | Completed | No outcome recorded |
| Phase 4 | NCT01381367 | Feb 2009 → Jun 2011 | chronic obstructive pulmonary disease | Far Eastern Memorial Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02012309 | Aug 2014 → Jun 2021 | HIV infectious disease, pneumococcal infection | University of Colorado, Denver | Unknown | No outcome recorded |
| Comparator or background therapy18 trials | ||||||
| Phase 1 | NCT06678607 Comparator | Nov 2023 → Jul 2024 | pneumococcal infection | Shanghai Reinovax Biologics Co.,LTD | Completed | No outcome recorded |
| Phase 1 | NCT04054752 Comparator | May → Nov 2023 | breast carcinoma, colorectal adenocarcinoma, urinary bladder carcinoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT05827874 Background | Apr → Oct 2023 | — | Janssen Research & Development, LLC | Completed | Missed primary |
| Phase 1 | NCT04265911 Comparator | Feb → Nov 2020 | — | Affinivax, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03803202 Comparator | Jan 2019 → Sep 2020 | bacterial pneumonia, pneumococcal infection | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT06678620 Comparator | Apr 2024 → Apr 2025 overdue | pneumococcal infection | Shanghai Reinovax Biologics Co.,LTD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03313037 Comparator | Oct 2017 → Dec 2018 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT02806284 Comparator | Jan 2001 → Jan 2008 | meningitis | Uppsala University | Completed | No outcome recorded |
| Phase 3 | NCT06177912 Comparator | Jan 2024 → Feb 2025 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05696080 Comparator | Feb 2023 → Feb 2024 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05633992 Comparator | Jan → May 2023 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT05569954 Comparator | Nov 2022 → Oct 2023 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05464420 Comparator | Aug 2022 → May 2023 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | Met primary |
| Phase 3 | NCT05393037 Comparator | Jul 2022 → Jul 2023 | pneumococcal infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT05420961 Comparator | Jul 2022 → May 2023 | streptococcal pneumonia | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT04875533 Comparator | Jun 2021 → May 2022 | pneumococcal infection | Pfizer | Completed | Mixed |
| Phase 3 | NCT03835975 Comparator | Feb 2019 → Feb 2020 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT03760146 Comparator | Dec 2018 → Dec 2019 | pneumococcal infection | Pfizer | Completed | Mixed |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PPSV23 | “Day 1 Immunization Pre-NT-I7:Td and Polio Day 64, Immunization Post-NT-I7: Hep A#1, Hep B#1 Day 106: Hep B#2 (Optional) 6 Month Post NT-I7 Vaccines (Optional): Polio, Hep A#2,...” NCT04054752 ↗21“The polyvalent (23-valent) pneumococcal vaccine, PPSV23, is the active comparator.” NCT05569954 ↗ |
| Known as | 23-valent pneumococcal polysaccharide vaccine | “Adults ≥65 years of age were enrolled into 1 of 3 cohorts based on their prior pneumococcal vaccination history (23-valent pneumococcal polysaccharide vaccine [PPSV23], PCV13,...” PMID 34839993 ↗ Nov 20212“The active control vaccine is a 23-valent pneumococcal polysaccharide vaccine (23-valent pneumococcal polysaccharide vaccine, PPSV23) produced by the Chengdu Institute of...” NCT06678607 ↗ “The active control vaccine is a 23-valent pneumococcal polysaccharide vaccine (23-valent pneumococcal polysaccharide vaccine, PPSV23) produced by the Chengdu Institute of...” NCT06678620 ↗ |
| Known as | Pneumovax | “single subcutaneous injection of 0.5 ml Pneumovax® (Sanofi Pasteur MSD AB, Lyon, France) (PPSV23)” NCT02806284 ↗ |
| Known as | PPSV23=Pneumovax, | “PPSV23=Pneumovax,” NCT02806284 ↗ |
| Modality | Vaccine | “The adult anti-pneumococcal vaccine was a 23-polyvalent pneumococcal vaccine” NCT01381367 ↗ |
| Route | Subcutaneous | “0.5 ml of which was given subcutaneously” NCT01381367 ↗ |